Cost-effectiveness of cognitive-behavioral therapy versus treatment as usual for anxiety disorders in children with autism spectrum disorder / Francisca J. A. VAN STEENSEL in Research in Autism Spectrum Disorders, 8-2 (February 2014)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 8-2 (February 2014) . - p.127-137 Titre : Cost-effectiveness of cognitive-behavioral therapy versus treatment as usual for anxiety disorders in children with autism spectrum disorder Type de document : Texte imprimé et/ou numérique Auteurs : Francisca J. A. VAN STEENSEL, Auteur ; Carmen D. DIRKSEN, Auteur ; Susan M. BOGELS, Auteur Article en page(s) : p.127-137 Langues : Anglais (eng) Mots-clés : Anxiety  CBT  TAU  Cost-effectiveness Index. décimale : PER Périodiques Résumé : Abstract The study's aim was to evaluate the cost-effectiveness of CBT compared to treatment as usual (TAU). In total, 49 children aged 8–18 years with ASD and comorbid anxiety disorders, and their parents, participated; 24 were assigned to CBT and 25 were assigned to TAU. Outcome measures were the percentage of children free from their primary anxiety disorder and quality adjusted life years (QALYs). Costs were measured using a retrospective cost-questionnaire. Effects and costs were assessed at pre-, post-, and three months after treatment. Effects and costs were not statistically different between CBT and TAU, however the incremental cost-effectiveness ratio (ICER) demonstrated that CBT dominates TAU. Bootstrapped ICERs demonstrated that CBT has a high probability to be more effective than TAU, however, the probability that either CBT or TAU is more costly did not differ much. Secondary analyses demonstrated fairly robust results. CBT seems a cost-effective intervention compared to TAU, however, long-term follow-ups and comparisons between CBT and specific TAUs are necessary. Cost-effectiveness analyses may help inform policy makers to decide how to treat anxiety disorders in children with ASD. En ligne : http://dx.doi.org/10.1016/j.rasd.2013.11.001 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=221 [article] Cost-effectiveness of cognitive-behavioral therapy versus treatment as usual for anxiety disorders in children with autism spectrum disorder [Texte imprimé et/ou numérique] / Francisca J. A. VAN STEENSEL, Auteur ; Carmen D. DIRKSEN, Auteur ; Susan M. BOGELS, Auteur . - p.127-137. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 8-2 (February 2014) . - p.127-137 Mots-clés : Anxiety  CBT  TAU  Cost-effectiveness Index. décimale : PER Périodiques Résumé : Abstract The study's aim was to evaluate the cost-effectiveness of CBT compared to treatment as usual (TAU). In total, 49 children aged 8–18 years with ASD and comorbid anxiety disorders, and their parents, participated; 24 were assigned to CBT and 25 were assigned to TAU. Outcome measures were the percentage of children free from their primary anxiety disorder and quality adjusted life years (QALYs). Costs were measured using a retrospective cost-questionnaire. Effects and costs were assessed at pre-, post-, and three months after treatment. Effects and costs were not statistically different between CBT and TAU, however the incremental cost-effectiveness ratio (ICER) demonstrated that CBT dominates TAU. Bootstrapped ICERs demonstrated that CBT has a high probability to be more effective than TAU, however, the probability that either CBT or TAU is more costly did not differ much. Secondary analyses demonstrated fairly robust results. CBT seems a cost-effective intervention compared to TAU, however, long-term follow-ups and comparisons between CBT and specific TAUs are necessary. Cost-effectiveness analyses may help inform policy makers to decide how to treat anxiety disorders in children with ASD. En ligne : http://dx.doi.org/10.1016/j.rasd.2013.11.001 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=221

A Cost of Illness Study of Children with High-Functioning Autism Spectrum Disorders and Comorbid Anxiety Disorders as Compared to Clinically Anxious and Typically Developing Children / Francisca J. A. STEENSEL in Journal of Autism and Developmental Disorders, 43-12 (December 2013)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 43-12 (December 2013) . - p.2878-2890 Titre : A Cost of Illness Study of Children with High-Functioning Autism Spectrum Disorders and Comorbid Anxiety Disorders as Compared to Clinically Anxious and Typically Developing Children Type de document : Texte imprimé et/ou numérique Auteurs : Francisca J. A. STEENSEL, Auteur ; Carmen D. DIRKSEN, Auteur ; Susan M. BOGELS, Auteur Article en page(s) : p.2878-2890 Langues : Anglais (eng) Mots-clés : ASD  Anxiety  Costs  Cost of illness Index. décimale : PER Périodiques Résumé : The study’s aim was to estimate the societal costs of children with high-functioning ASD and comorbid anxiety disorder(s) (ASD + AD-group; n = 73), and to compare these costs to children with anxiety disorders (AD-group; n = 34), and typically developing children (controls; n = 87). Mean total costs for the ASD + AD-group amounted €17,380 per year. Societal costs were estimated at almost 142 million euro per year. Costs in the ASD + AD-group were four times higher compared to the AD-group, and 27 times higher compared to controls. ASD-related costs were higher in the ASD + AD-group; anxiety-related costs did not differ between the ASD + AD- and AD-group; costs due to physical or other reasons did not differ across groups. The findings suggest that costs can be decreased if effective treatment options for treating anxiety in ASD are established, however, the remaining costs associated with ASD would still be large. A limitation of the study is that a group of children with ASD without anxiety disorders is lacking. En ligne : http://dx.doi.org/10.1007/s10803-013-1835-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=218 [article] A Cost of Illness Study of Children with High-Functioning Autism Spectrum Disorders and Comorbid Anxiety Disorders as Compared to Clinically Anxious and Typically Developing Children [Texte imprimé et/ou numérique] / Francisca J. A. STEENSEL, Auteur ; Carmen D. DIRKSEN, Auteur ; Susan M. BOGELS, Auteur . - p.2878-2890. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 43-12 (December 2013) . - p.2878-2890 Mots-clés : ASD  Anxiety  Costs  Cost of illness Index. décimale : PER Périodiques Résumé : The study’s aim was to estimate the societal costs of children with high-functioning ASD and comorbid anxiety disorder(s) (ASD + AD-group; n = 73), and to compare these costs to children with anxiety disorders (AD-group; n = 34), and typically developing children (controls; n = 87). Mean total costs for the ASD + AD-group amounted €17,380 per year. Societal costs were estimated at almost 142 million euro per year. Costs in the ASD + AD-group were four times higher compared to the AD-group, and 27 times higher compared to controls. ASD-related costs were higher in the ASD + AD-group; anxiety-related costs did not differ between the ASD + AD- and AD-group; costs due to physical or other reasons did not differ across groups. The findings suggest that costs can be decreased if effective treatment options for treating anxiety in ASD are established, however, the remaining costs associated with ASD would still be large. A limitation of the study is that a group of children with ASD without anxiety disorders is lacking. En ligne : http://dx.doi.org/10.1007/s10803-013-1835-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=218

Societal costs of subclinical depressive symptoms in Dutch adolescents: a cost-of-illness study / Denise H. M. BODDEN in Journal of Child Psychology and Psychiatry, 63-7 (July 2022)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 63-7 (July 2022) . - p.771-780 Titre : Societal costs of subclinical depressive symptoms in Dutch adolescents: a cost-of-illness study Type de document : Texte imprimé et/ou numérique Auteurs : Denise H. M. BODDEN, Auteur ; Marieke W. H. VAN DEN HEUVEL, Auteur ; Rutger C. M. E. ENGELS, Auteur ; Carmen D. DIRKSEN, Auteur Article en page(s) : p.771-780 Langues : Anglais (eng) Mots-clés : Adolescent  Cost-Benefit Analysis  Depression/epidemiology  Depressive Disorder, Major  Humans  Reproducibility of Results  Surveys and Questionnaires  Adolescence  depression  economic evaluation Index. décimale : PER Périodiques Résumé : BACKGROUND: Subclinical depressive symptoms are highly prevalent among adolescents and are associated with negative consequences, which may pose an economic burden for society. We conducted a prevalence-based cost-of-illness study using a societal perspective to investigate the cost-of-illness of subclinical depressive symptoms among adolescents. METHODS: Using a bottom-up approach, cost questionnaires were assessed to measure costs from 237 Dutch families with an adolescent aged 11-18 with subclinical depressive symptoms (of which 34 met the criteria of a depressive disorder). The study is registered in the Dutch Trial Register (Trial NL5584/NTR6176; www.trialregister.nl/trial/5584). RESULTS: Our calculations show that adolescents with subclinical depressive symptoms cost the Dutch society more than ?42?million annually, expressed in costs related to depressive symptoms. Secondary analyses were performed to test the reliability and stability of the costs. When costs related to psychological problems were considered, the annual costs amounted to ?67?million. The total societal costs related to physical problems amounted to approximately ?126?million. All costs combined (depressive, psychological, behavioural and physical problems and other reasons) amounted to a ?243?million. Total costs were highest for physical-related problems of the adolescent (52% of the total costs), followed by psychological (28%), depressive (17%) and behavioural problems (1%). Using an international prevalence rate, societal costs related to depressive symptoms resulted in ?54?million a year. CONCLUSIONS: Cost-effective prevention programmes seem warranted given the high societal costs and risk of future costs as subclinical depressive symptoms could be a precursor of clinical depression later in life. En ligne : http://dx.doi.org/10.1111/jcpp.13517 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=477 [article] Societal costs of subclinical depressive symptoms in Dutch adolescents: a cost-of-illness study [Texte imprimé et/ou numérique] / Denise H. M. BODDEN, Auteur ; Marieke W. H. VAN DEN HEUVEL, Auteur ; Rutger C. M. E. ENGELS, Auteur ; Carmen D. DIRKSEN, Auteur . - p.771-780. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 63-7 (July 2022) . - p.771-780 Mots-clés : Adolescent  Cost-Benefit Analysis  Depression/epidemiology  Depressive Disorder, Major  Humans  Reproducibility of Results  Surveys and Questionnaires  Adolescence  depression  economic evaluation Index. décimale : PER Périodiques Résumé : BACKGROUND: Subclinical depressive symptoms are highly prevalent among adolescents and are associated with negative consequences, which may pose an economic burden for society. We conducted a prevalence-based cost-of-illness study using a societal perspective to investigate the cost-of-illness of subclinical depressive symptoms among adolescents. METHODS: Using a bottom-up approach, cost questionnaires were assessed to measure costs from 237 Dutch families with an adolescent aged 11-18 with subclinical depressive symptoms (of which 34 met the criteria of a depressive disorder). The study is registered in the Dutch Trial Register (Trial NL5584/NTR6176; www.trialregister.nl/trial/5584). RESULTS: Our calculations show that adolescents with subclinical depressive symptoms cost the Dutch society more than ?42?million annually, expressed in costs related to depressive symptoms. Secondary analyses were performed to test the reliability and stability of the costs. When costs related to psychological problems were considered, the annual costs amounted to ?67?million. The total societal costs related to physical problems amounted to approximately ?126?million. All costs combined (depressive, psychological, behavioural and physical problems and other reasons) amounted to a ?243?million. Total costs were highest for physical-related problems of the adolescent (52% of the total costs), followed by psychological (28%), depressive (17%) and behavioural problems (1%). Using an international prevalence rate, societal costs related to depressive symptoms resulted in ?54?million a year. CONCLUSIONS: Cost-effective prevention programmes seem warranted given the high societal costs and risk of future costs as subclinical depressive symptoms could be a precursor of clinical depression later in life. En ligne : http://dx.doi.org/10.1111/jcpp.13517 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=477

---

1 (1 - 3 / 3)